payments and royalties on product sales.
-- Achievement of multiple milestones in Dow AgroSciences collaboration.
As part of their joint Research and Commercial License Agreement the
companies achieved milestones that represent the successful
application of Sangamo's ZFP technology to the generation of specific
traits in two major crop species -- maize and canola.
-- Sangamo closed a registered direct offering to institutional
investors. In July, Sangamo sold an aggregate of 3,278,689 shares of
common stock to a group of institutional investors in a registered
direct offering, resulting in gross proceeds to the company of
approximately $30 million before fees and expenses.
-- Appointment of H. Ward Wolff as Executive Vice President and Chief
Financial Officer (CFO). In December 2007, Mr. Wolff joined
Sangamo's senior management team after serving on the Board of
Directors of the Company since June 2006. In this newly created
position, Mr. Wolff oversees the company's administrative, financial
and business development activities and operations.
-- Sangamo hosted an Investor and Analyst Briefing. On December 5,
Sangamo provided an update on its achievements in 2007, its
therapeutic programs, progress in its collaboration with Dow
AgroSciences and its objectives for 2008 during its annual Investor
and Analyst Briefing held in New York. The event was webcast and the
replay is available on Sangamo's website at
In today's conference call members of Sangamo's management team will
discuss the company's plans and objectives for 2008 that include:
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved